Remove Patients Remove Pharmacology Remove Prescription Remove Side effects
article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala. “By By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”

article thumbnail

How NLP Helps Life Sciences Companies Unlock Insights from Drug Labels

PM360

Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S. Understanding patient sub-group exceptions for competitive or for label development purposes. Food and Drug Administration (FDA) or European Medicines Agency (EMA). Challenges in Working with Label Data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to Get into Pharmaceutical Sales

Rep-Lite

Pharmaceutical Sales refers to selling prescription and over-the-counter (OTC) medications, medical devices, and other healthcare products to healthcare professionals, or medical providers such as doctors, pharmacists, and hospitals. Be patient with yourself and understand that you might face challenges along the way.

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

The system uses the patient’s EEG data to calculate a value for the amygdala-derived-EFP biomarker, and meanwhile the patient tries various mental strategies that may help to reduce the value. These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

The company is aiming to enrol the first patient in the ALETTA Phase III trial in Q1 or Q2 of 2023, says Dr. Jan van der Mooren, Freya’s chief medical officer (CMO). Moreover, any potential use of Lybrido or Lybridos would also come with a screening test that will determine which of these drugs will benefit the patient, says Simon.